CD44 and prostate carcinoma: These results were confirmed in a subsequent study which additionally verified the expression of CD44, a marker of basal prostatic epithelial cells, and found it to have a concurrent expression with MAO-A, suggesting that high-grade prostate cancer may display a basal or perhaps a progenitor cell-like phenotype.